Is AOD-9604 Legal in Missouri?

What AOD-9604 Actually Is

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to residues 176 through 191 of human growth hormone (hGH), with a tyrosine added at the N-terminus to aid stability. The compound was originally developed by Metabolic Pharmaceuticals in Australia during the late 1990s as a potential anti-obesity drug, under the reasoning that this C-terminal fragment retained hGH's lipolytic activity without triggering IGF-1-mediated growth effects.

Mechanism of Action

The peptide is believed to stimulate fat breakdown through beta-3 adrenergic receptor pathways and may inhibit lipogenesis. A 12-week Phase II randomized controlled trial published in 2001 (N=300) reported a statistically significant reduction in body weight at a dose of 1 mg/day oral administration compared to placebo, though the absolute mean difference was modest at approximately 1.4 kg [1]. The compound never advanced to Phase III trials in the United States, and no New Drug Application (NDA) was filed with the FDA.

Why It Is Not Approved

The FDA has not approved AOD-9604 for any therapeutic indication. Without an approved NDA, the compound cannot be marketed as a drug in the U.S. [2]. This is the foundational legal fact from which all state-level analysis follows.

Federal Legal Framework Governing AOD-9604

Federal law governs drug approval, compounding pharmacy standards, and the legality of dispensing unapproved active pharmaceutical ingredients (APIs). Missouri practitioners must understand this framework before advising patients.

FDA Drug Approval Status

AOD-9604 is not listed in the FDA's Orange Book of approved drug products [2]. It has no approved NDA, no Abbreviated New Drug Application (ANDA), and no Biologics License Application (BLA). Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), distributing or dispensing an unapproved new drug to patients is unlawful unless an exemption applies, such as an active Investigational New Drug (IND) application or a valid compounding exemption [3].

The 503A Compounding Framework

Section 503A of the FD&C Act allows state-licensed pharmacies to compound drugs for individual patients under a valid prescription without holding an FDA drug approval, provided the compounded drug meets specific conditions. One condition is that the active ingredient must either appear on FDA's approved bulk substances list or be a component of an FDA-approved drug [3].

The FDA maintains a publicly posted list of bulk drug substances that may be used in 503A compounding. AOD-9604 was nominated for evaluation and placed on FDA's "Category 2" list, which means the agency received the nomination but has not yet determined whether the substance meets the criteria for inclusion on the positive list [4]. A Category 2 designation is not an approval. Compounding pharmacies operating under 503A cannot legally use a Category 2 substance to prepare patient-specific compounds until the FDA completes its evaluation and moves it to a positive list [4].

This is the clearest federal restriction affecting Missouri patients and prescribers today.

The 503B Outsourcing Facility Framework

Section 503B of the FD&C Act created a separate pathway for larger-scale outsourcing facilities that register with the FDA and compound drugs without patient-specific prescriptions. These facilities may only compound drugs that appear on FDA's 503B-specific bulk substances list, or drugs that are copies of commercially available products [3]. AOD-9604 does not appear on the 503B positive list, so registered outsourcing facilities also cannot legally compound and distribute it for clinical use.

Research and Analytical Use

Federal law does permit the purchase and possession of AOD-9604 as an analytical reference standard or research chemical by licensed laboratories and researchers, provided it is not intended for human administration. Several chemical suppliers sell AOD-9604 labeled "for research use only" under this exemption. Purchasing such material for self-administration or prescribing it to patients falls outside this exemption and carries significant legal exposure [3].

Missouri State Law and AOD-9604

Missouri has not enacted any statute that specifically names AOD-9604 or that independently bans or permits compounded peptides beyond what federal law already establishes. That means the analysis defaults entirely to the federal framework above.

Missouri State Board of Pharmacy

The Missouri State Board of Pharmacy licenses and regulates pharmacies operating in Missouri, including compounding pharmacies. Missouri compounding regulations align with the federal 503A and 503B frameworks [5]. A Missouri-licensed compounding pharmacy that prepared AOD-9604 for patient dispensing would be violating federal law as interpreted by the FDA's Category 2 designation, and would also be subject to state board disciplinary action for compounding with a non-authorized bulk substance.

Missouri Medical Practice Act

Missouri's Medical Practice Act (RSMo Chapter 334) governs physician prescribing. Missouri physicians have broad prescribing authority for FDA-approved drugs and, under certain conditions, for unapproved uses of approved drugs (off-label prescribing). Prescribing an unapproved API that cannot be legally compounded or dispensed creates practical and liability problems even if the prescription itself is not explicitly prohibited by state statute. A Missouri physician who writes a prescription for AOD-9604 knowing it will be filled by a compounding pharmacy in violation of federal 503A rules may face professional liability risk.

Controlled Substance Scheduling in Missouri

AOD-9604 is not listed as a controlled substance under the federal Controlled Substances Act or under Missouri's Uniform Controlled Substances Law (RSMo Chapter 195) [6]. This means possession of AOD-9604 for personal use does not carry the criminal penalties associated with Schedule I or II substances. However, absence from the controlled substance schedules does not make a compound legal to dispense as a drug. The relevant restriction comes from the FD&C Act's unapproved drug provisions, not from scheduling law.

How Patients in Missouri Currently Attempt to Access AOD-9604

Despite the legal constraints, AOD-9604 remains widely available through channels that operate in varying degrees of legal risk.

Online "Research Chemical" Vendors

Numerous websites sell AOD-9604 as a lyophilized powder labeled for research use only, often packaged in vials with bacteriostatic water. These products are not FDA-inspected, have no guaranteed purity or potency, and are sold without a prescription. Purchasing such products for self-injection is illegal under the FD&C Act's provisions on unapproved new drugs and carries real safety risk from contaminated or mislabeled batches [3].

Compounding Pharmacies Operating Outside Compliance

Some compounding pharmacies, particularly those operating primarily online, continue to dispense AOD-9604 despite the FDA's Category 2 designation. Patients should understand that these pharmacies are not in compliance with federal 503A standards. The FDA has sent warning letters to compounding pharmacies dispensing other Category 2 peptides, such as BPC-157 and selank, and similar enforcement action targeting AOD-9604 is plausible [4].

Telehealth Platforms

Telehealth prescribing platforms have expanded access to peptide therapies broadly. In Missouri, a telehealth practitioner can legally evaluate a patient and write a prescription. The dispensing side, however, remains constrained by the 503A Category 2 restriction. Patients receiving AOD-9604 through telehealth platforms in Missouri should ask the prescriber specifically which compounding pharmacy will fill the compound and whether that pharmacy's use of AOD-9604 is consistent with current FDA bulk substance lists.

The HealthRX clinical team uses a three-question compliance screen before recommending any compounded peptide to Missouri patients:

1. Is the active ingredient on FDA's 503A positive list or 503B positive list?
2. Has the compounding pharmacy undergone third-party USP 797/800 inspection within the last 12 months?
3. Does the pharmacy provide a certificate of analysis (COA) from an accredited analytical lab confirming identity, potency, and sterility?

AOD-9604 currently fails Question 1 under the 503A framework, which means the HealthRX team does not direct Missouri patients to compounding pharmacies for this compound at this time.

Clinical Evidence: What the Trials Actually Show

Understanding the clinical evidence matters because it contextualizes why the FDA has not prioritized evaluating AOD-9604 for the positive bulk substances list.

Phase II Weight-Loss Data

The most-cited human trial is a Phase II dose-finding study by Metabolic Pharmaceuticals that enrolled approximately 300 adults with obesity [1]. Participants received oral AOD-9604 at 1 mg/day, and at 12 weeks the 1 mg group showed a mean weight reduction of approximately 1.4 kg greater than placebo. The authors noted the result was statistically significant but acknowledged the effect size was small compared to available pharmacotherapy at the time.

No Phase III replication followed. The company did not pursue FDA approval, and the compound was later explored in oral form for osteoarthritis (under the name Trafigura/AOD9604) without reaching regulatory submission in the U.S.

IGF-1 and Safety Profile

One reason AOD-9604 attracted interest is its reported separation from IGF-1 stimulation. A small pharmacokinetic study found that subcutaneous AOD-9604 did not significantly raise serum IGF-1 concentrations in healthy volunteers, which distinguished it from full-sequence recombinant hGH [1]. This safety signal is real but based on short-duration, small-sample data. Long-term safety data in humans remain absent.

The Endocrine Society's clinical practice guideline on growth hormone use in adults states explicitly that peptide secretagogues and fragments with unproven safety profiles should not be used outside of clinical trials, citing inadequate evidence for benefit and unknown risk [7].

Anti-Doping Status

The World Anti-Doping Agency (WADA) prohibits AOD-9604 under its "peptide hormones, growth factors, related substances and mimetics" category (S2), effective as of the current WADA Prohibited List. Missouri athletes subject to WADA-aligned testing (NCAA, USADA-affiliated sports) face disqualification risk from AOD-9604 use regardless of its legal classification as a drug or research chemical.

What Missouri Prescribers Should Know

Physicians, nurse practitioners, and physician assistants licensed in Missouri face several practical considerations when patients ask about AOD-9604.

Informed Consent and Liability

Writing a prescription for a compound that a pharmacy cannot legally fill under current federal standards does not automatically constitute malpractice, but it does create documentation complexity. If a patient self-sources AOD-9604 from an online vendor after a clinical consultation, the prescriber's liability exposure depends on whether the practitioner's documentation clearly communicated the unapproved status and the risks of obtaining the compound outside a licensed pharmacy.

Alternatives With Clearer Legal Footing

Several weight-management agents have full FDA approval and established Phase III evidence. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% with placebo, a result that is both statistically and clinically significant [8]. Tirzepatide 15 mg (Zepbound) produced 20.9% mean body weight loss at 72 weeks in SURMOUNT-1 (N=2,539) versus 3.1% with placebo [9]. Both agents are available through Missouri pharmacies with a standard prescription and are covered by an expanding set of insurance plans.

For practitioners whose patients specifically request peptide-based options, CJC-1295 combined with ipamorelin remains on FDA's 503A Category 1 consideration pathway and is dispensed by many compliant compounding pharmacies, though that list's status should be verified at the time of prescribing.

Monitoring the FDA Bulk Substances Process

The FDA's evaluation process for Category 2 bulk substances is ongoing and the list does change. The FDA posts updates to the bulk drug substances lists on its website [4]. Missouri prescribers with a clinical interest in peptide therapies should monitor this list quarterly, as a substance can move from Category 2 to the positive list or to the "do not compound" list based on FDA review outcomes.

"The FDA's bulk drug substance program under 503A is designed to ensure that compounded preparations are safe and clinically appropriate," the agency stated in its 2019 guidance document on bulk drug substances for compounding. "Substances that have not been evaluated should not be compounded until the Agency has had the opportunity to assess them." [4]

This statement from FDA guidance directly applies to AOD-9604's current Category 2 status.

Summary of Legal Risk by Access Method in Missouri

The table below maps each common access method to its legal risk profile under current federal and Missouri state law.

| Access Method | Federal Legal Status | Missouri State Risk | Recommended? | |---|---|---|---| | Licensed 503A compounding pharmacy | Non-compliant (Category 2 restriction) | State board exposure | No | | Licensed 503B outsourcing facility | Non-compliant (not on 503B list) | State board exposure | No | | Online "research chemical" vendor | Illegal for human use (FD&C Act) | No added state penalty | No | | Active FDA-approved IND protocol | Legal | Legal | Yes, if applicable | | FDA-approved weight-loss drug alternative | Legal | Legal | Yes |